Corcept Therapeutics Incorporated

23.80+0.5500+2.37%Vol 1.31M1Y Perf 2.56%
Jun 24th, 2022 16:00 DELAYED
BID18.02 ASK25.88
Open23.52 Previous Close23.25
Pre-Market- After-Market24.99
 - -  1.19 5.00%
Target Price
26.83 
Analyst Rating
Moderate Buy 1.83
Potential %
12.73 
Finscreener Ranking
★★★+     50.79
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★★+     59.77
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★★     72.72
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
80.92 
Earnings Rating
Strong Sell
Market Cap2.53B 
Earnings Date
4th Aug 2022
Alpha0.01 Standard Deviation0.14
Beta0.54 

Today's Price Range

23.0323.83

52W Range

15.8325.68

5 Year PE Ratio Range

10.80297.40

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
14.98%
1 Month
19.36%
3 Months
-0.71%
6 Months
19.90%
1 Year
2.56%
3 Years
130.40%
5 Years
89.94%
10 Years
440.91%

TickerPriceChg.Chg.%
CORT23.800.55002.37
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Financial StrengthValueIndustryS&P 500US Markets
6.50
6.80
0.00
0.01
-
Leverage Ratio 1.10
ProfitabilityValueIndustryS&P 500US Markets
98.60
34.60
35.40
36.50
29.38
RevenueValueIndustryS&P 500US Markets
380.23M
3.58
11.05
27.41
Earnings HistoryEstimateReportedSurprise %
Q01 20220.230.20-13.04
Q04 20210.220.2618.18
Q03 20210.190.2426.32
Q02 20210.140.2150.00
Q01 20210.210.18-14.29
Q04 20200.200.200.00
Q03 20200.210.17-19.05
Q02 20200.200.2315.00
Earnings Per EndEstimateRevision %Trend
6/2022 QR0.21-16.00Negative
9/2022 QR0.230.00-
12/2022 FY0.870.00-
12/2023 FY0.99-4.81Negative
Next Report Date4th Aug 2022
Estimated EPS Next Report0.21
Estimates Count4
EPS Growth Next 5 Years %11.20
Volume Overview
Volume1.31M
Shares Outstanding106.25K
Shares Float68.49M
Trades Count11.29K
Dollar Volume31.07M
Avg. Volume696.20K
Avg. Weekly Volume622.42K
Avg. Monthly Volume668.30K
Avg. Quarterly Volume797.88K

Corcept Therapeutics Incorporated (NASDAQ: CORT) stock closed at 23.8 per share at the end of the most recent trading day (a 2.37% change compared to the prior day closing price) with a volume of 1.31M shares and market capitalization of 2.53B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 236 people. Corcept Therapeutics Incorporated CEO is Joseph K. Belanoff.

The one-year performance of Corcept Therapeutics Incorporated stock is 2.56%, while year-to-date (YTD) performance is 20.2%. CORT stock has a five-year performance of 89.94%. Its 52-week range is between 15.825 and 25.68, which gives CORT stock a 52-week price range ratio of 80.92%

Corcept Therapeutics Incorporated currently has a PE ratio of 23.50, a price-to-book (PB) ratio of 5.58, a price-to-sale (PS) ratio of 5.75, a price to cashflow ratio of 14.70, a PEG ratio of 2.32, a ROA of 22.60%, a ROC of 24.16% and a ROE of 25.13%. The company’s profit margin is 29.38%, its EBITDA margin is 35.40%, and its revenue ttm is $380.23 Million , which makes it $3.58 revenue per share.

Of the last four earnings reports from Corcept Therapeutics Incorporated, there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.21 for the next earnings report. Corcept Therapeutics Incorporated’s next earnings report date is 04th Aug 2022.

The consensus rating of Wall Street analysts for Corcept Therapeutics Incorporated is Moderate Buy (1.83), with a target price of $26.83, which is +12.73% compared to the current price. The earnings rating for Corcept Therapeutics Incorporated stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Corcept Therapeutics Incorporated has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Corcept Therapeutics Incorporated has a Buy technical analysis rating based on Technical Indicators (ADX : 17.38, ATR14 : 0.84, CCI20 : 257.14, Chaikin Money Flow : 0.23, MACD : 0.49, Money Flow Index : 72.56, ROC : 11.11, RSI : 69.91, STOCH (14,3) : 99.18, STOCH RSI : 1.00, UO : 67.04, Williams %R : -0.82), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Corcept Therapeutics Incorporated in the last 12-months were: Daniel N. Swisher (Option Excercise at a value of $49 125), Daniel N. Swisher (Sold 7 500 shares of value $162 741 ), David L. Mahoney (Option Excercise at a value of $121 500), G. Charles Robb (Option Excercise at a value of $799 999), G. Charles Robb (Sold 102 500 shares of value $2 122 747 ), Hazel Hunt (Option Excercise at a value of $277 300), James N. Wilson (Option Excercise at a value of $624 000), Sean Maduck (Option Excercise at a value of $538 300), Sean Maduck (Sold 150 000 shares of value $3 203 270 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (66.67 %)
4 (66.67 %)
4 (66.67 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (16.67 %)
1 (16.67 %)
1 (16.67 %)
Moderate Sell
1 (16.67 %)
1 (16.67 %)
1 (16.67 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.83
Moderate Buy
1.83
Moderate Buy
1.83

Corcept Therapeutics Incorporated

Corcept Therapeutics Inc is engaged in the discovery, development, and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders by modulating the effects of cortisol.

CEO: Joseph K. Belanoff

Telephone: +1 650 327-3270

Address: 149 Commonwealth Drive, Menlo Park 94025, CA, US

Number of employees: 236

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

80%20%

Bearish Bullish

68%32%

Bearish Bullish

63%37%

TipRanks News for CORT

Wed, 16 Feb 2022 11:15 GMT Analysts Top Healthcare Picks: Corcept Therapeutics (CORT), Stealth Biotherapeutics (MITO)

- TipRanks. All rights reserved.

News

Stocktwits